Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPLITUDE: adaptive phase 2/3 study of VX-147 in APOL1-mediated proteinuric kidney disease
PACTR202301768862135Phase 2Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of inaxaplin in APOL1-mediated kidney disease (AMKD) and chronic kidney disease (CKD) (4 arms), sponsored by Vertex Pharmaceuticals. Started Mar 2023; status: recruiting.
02
Drugs
inaxaplin
03
Conditions
APOL1-mediated kidney disease (AMKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on PACTR202301768862135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202301768862135.